

# CAN WE USE *DE-NOVO* mTOR INHIBITORS IN HYPERSENSITIZED KIDNEY TRANSPLANT RECIPIENTS?

Lack of clinical experience in high immunological risk kidney transplant recipients treated with mTOR inhibitors



Almost all clinical trials that analyzed calcineurin (CNI) and mTOR inhibitors (mTORi) combination have excluded hypersensitized patients from enrollment

**CLÍNICA**  
BARCELONA  
Hospital Universitari




Single-center clinical experience (2013-2016) with cPRA I+II > 50%

- Tacrolimus + Mycophenolate + PDN (n=38)
- Tacrolimus + mTORi + PDN (n=33)

mTOR normal range (3-8 ng/ml)

1-year rejection-free survival favored the mTORi group compared to the mycophenolate group



No difference in 1-year graft function, chronicity scores and DSA development

Cucchiari D et al. *Transplantation*. August 2020

@TransplantJrnl @CucchiariD

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved

**Transplantation**<sup>®</sup>

